Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Richard Malkoun"'
Autor:
Lilian Laborde, Julien Mazières, Fabrice Barlesi, Jacques Fieschi, Maurice Pérol, Vanina Leca, Alboukadel Kassambara, Florence Monville, Maryannick Le Ray, Marie Roumieux, Richard Malkoun, Arnaud Boyer, Louisiane Lebas, Hervé Pegliasco, Patricia Barré, Clarisse Audigier-valette, Sarah Zahi, Stéphane Hominal, Laurent Greillier, Marcellin Landri, Margot Vasseur, Chafik Hamdad, Margaux Mercadal, Laurent Vanhille, Sebastien Benzekry, Stephanie Martinez, Patrice Ray, Lionel Falchero, Antoine Serre, Nicolas Cloarec, Ahmed Frikha, Pierre Bory
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/3db15db2b42e4d59aecc521d1217d797
Autor:
Noémie Resseguier, Julien Mazières, Fabrice Barlesi, Maurice Pérol, Thomas Sbarrato, Fanny Arnoux, Stéphane Garcia, Jacques Fieschi-Meric, Vanina Leca, Alboukadel Kassambara, Lamia Ghezali, Pernelle Outters, Christelle Cotteaux-Lautard, Florence Monville, Maryannick Le Ray, Marie Roumieux, Richard Malkoun, Arnaud Boyer, Louisiane Lebas, Hervé Pegliasco, Patricia Barré, Clarisse Audigier-valette, Sarah Zahi, Luc Odier, Stéphane Hominal, Laurent Greillier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/3b2736fc933c4d1c8782c09fa6c847bc
Autor:
Lamia Ghezali, Marcellin Landri, Florence Monville, Vanina Leca, Théo Vasse, Chafik Hamdad, Margaux Mercadal, Laurent Vanhille, Alboukadel Kassambara, Thomas Sbarrato, Maryannick Le Ray, Marie Roumieux, Richard Malkoun, Noémie Resseguier, Arnaud Boyer, Clarisse Audigier-Valette, Stephanie Martinez, Hervé Pegliasco, Patrice Ray, Lionel Falchero, Antoine Serre, Nicolas Cloarec, Louisiane Lebas, Stéphane Hominal, Patricia Barré, Sarah Zahi, Ahmed Frikha, Pierre Bory, Lilian Laborde, Julien Mazières, Virginie Martin, Maurice Pérol, Laurent Greillier, Fabrice Barlesi, Jacques Fieschi
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db52b4a1e6f788cc54244733fc403d7b
https://doi.org/10.1136/jitc-2022-sitc2022.0701
https://doi.org/10.1136/jitc-2022-sitc2022.0701
Autor:
Laurent Greillier, Florence Monville, Vanina Leca, Frédéric Vely, Stephane Garcia, Joseph Ciccolini, Florence Sabatier, Gilbert Ferrani, Nawel Boudai, Lamia Ghezali, Marcellin Landri, Clémence Marin, Mourad Hamimed, Laurent Arnaud, Melanie Karlsen, Kevin Atsou, Sivan Bokobza, Pauline Fleury, Arnaud Boyer, Clarisse Audigier-Valette, Stéphanie Martinez, Hervé Pegliasco, Patrice Ray, Lionel Falchero, Antoine Serre, Nicolas Cloarec, Louisiane Lebas, Stephane Hominal, Patricia Barre, Sarah Zahi, Ahmed Frikha, Pierre Bory, Maryannick Le Ray, Lilian Laborde, Virginie Martin, Richard Malkoun, Marie Roumieux, Julien Mazieres, Maurice Perol, Eric Vivier, Sebastien Benzekry, Jacques Fieschi, Fabrice Barlesi
Publikováno v:
Cancer Research. 82:LB120-LB120
Background: Resistance to PD1/L1 immune checkpoint inhibitors (ICIs) in advanced NSCLC patients is observed in about 80% of individuals with no robust predictive biomarker yet. The PIONeeR trial (NCT03493581) aims to predict such resistances through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08ecc3054e7a6ebaa44d60b4295406db
https://doi.org/10.1158/1538-7445.am2022-lb120
https://doi.org/10.1158/1538-7445.am2022-lb120
Autor:
Vanina Leca, Alboukadel Kassambara, Lamia Ghezali, Pernelle Outters, Christelle Cotteaux-Lautard, Fanny Arnoux, Thomas Sbarrato, Florence Monville, Maryannick Le Ray, Marie Roumieux, Stephane Garcia, Richard Malkoun, Noémie Resseguier, Arnaud Boyer, Louisiane Lebas, Hervé Pegliasco, Patricia Barré, Clarisse Audigier-valette, Sarah Zahi, Luc Odier, Stéphane Hominal, Maurice Perol, Julien Mazieres, Laurent Greillier, Fabrice Barlesi, Jacques Fieschi-Meric
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPD1/L1 Immune Checkpoint Inhibitors (ICI) have significantly improved long-term outcome in about 20% of advanced Non Small Cells Lung Cancer (NSCLC) patients (pts), but 80% present primary or secondary resistance. The PIONeeR project (NCT03
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4da7b174201ee0960add2de3bc9946c4
https://doi.org/10.1136/jitc-2021-sitc2021.460
https://doi.org/10.1136/jitc-2021-sitc2021.460